The research team, led by investigators at the Fred Hutchinson Cancer Center in Seattle, surveyed 459 cancer survivors who were, on average, eleven years past their initial diagnosis. That long follow-up window is significant. Most studies of financial toxicity in oncology focus on patients in active treatment, when bills are arriving in a torrent. This study instead asked whether the administrative aftermath of cancer persists long into survivorship, and the answer appears to be yes: 46 percent of participants reported experiencing at least one insurance-related administrative burden.

The researchers examined five distinct categories of administrative burden. Prior authorization, the requirement that an insurer approve a treatment before it is delivered, was reported by 33 percent of survivors who had received immunotherapy. Surprise bills, unexpected charges for services patients believed were covered, affected 46 percent of immunotherapy recipients and 33 percent of those who had undergone surgery. Stepped care, in which insurers require patients to try less expensive therapies before approving others, was reported by 26 percent of immunotherapy patients and 17 percent of chemotherapy recipients. Claim denials were reported by 22 percent of chemotherapy patients and 24 percent of those who had received radiation therapy, while out-of-network charges affected 16 percent of surgical patients. All of these associations were statistically significant.

Perhaps the most striking result is what did not predict these burdens. The type of health insurance a survivor had at the time of diagnosis, whether employer-sponsored, public or otherwise, showed no statistically significant association with the likelihood of experiencing administrative burdens. In other words, the paperwork gauntlet appears to cut across the American insurance landscape, afflicting the privately insured and publicly insured alike. This challenges a common assumption that problems with prior authorization and denials are concentrated in particular insurance products or payer categories.

The study also measured financial toxicity across four dimensions, a framework that treats the financial fallout of cancer as a genuine clinical side effect rather than a mere accounting problem. Financial toxicity encompasses out-of-pocket costs, but also the psychological distress of debt, the behavioral changes families make to cope with bills, and the anxiety and depression that money worries generate. Previous research has linked high financial toxicity to worse quality of life, greater psychological distress and even earlier mortality among patients with cancer, making it a target for intervention in its own right.

Here the treatment picture diverged from the burden picture. Survivors who had undergone surgery, chemotherapy or immunotherapy reported significantly more financial coping behaviors than those who had not received those treatments, meaning they had taken concrete steps to manage the financial damage, such as borrowing, cutting expenses or working extra hours. Insurance type mattered in a narrower way: compared with survivors covered by employer- or school-sponsored insurance, those who had purchased their own insurance reported more financial depression, anxiety and coping. Most other insurance types showed no such association.

Why would immunotherapy and chemotherapy carry such heavy administrative loads? The authors point to the mechanics of how these drugs are approved and paid for. Immunotherapies, which have transformed the treatment of melanoma and many other cancers since the first checkpoint inhibitor was approved in 2011, are among the most expensive injectable drugs in medicine, and their costs have continued to climb after launch. Expensive, specialty drugs are precisely the category that insurers police most aggressively with prior authorization requirements, step therapy protocols and utilization review. Chemotherapy, similarly, sits at the intersection of high cost and complex billing, where coding disputes and coverage questions can easily harden into formal denials.

Surgery and radiation therapy carry different risks. Surgical patients in the study were more likely to report surprise bills and out-of-network charges, a pattern consistent with the well-documented problem of ancillary providers, such as anesthesiologists and pathologists, participating in an operation while remaining outside the patient’s insurance network. Radiation oncology has also been identified in prior literature as a field where prior authorization imposes substantial delays and administrative work. The new findings suggest that no major cancer treatment modality is free of administrative risk, even if the specific burden differs by modality.

The implications for survivors and clinicians are considerable. The study’s authors note that immunotherapy and chemotherapy may confer the highest risk of administrative burdens, but that surgery and radiation can also expose patients to them. Because insurance type at diagnosis did not predict burdens, clinicians cannot easily identify which patients will need help simply by looking at their coverage. Instead, the treatment received may serve as a better signal, allowing financial navigators and care teams to target screening and assistance toward patients whose treatment plans carry elevated administrative risk. Financial navigation programs, which have shown promising primary outcomes in randomized trials for newly diagnosed patients, may need to extend their reach deeper into survivorship.

The research also contributes to a growing social science literature on administrative burden, the learning, compliance and psychological costs that citizens pay when interacting with state and bureaucratic systems. Applied to health insurance, this framework reframes prior authorizations and denials not as isolated annoyances but as a cumulative tax on patients’ time, attention and emotional reserves, levied on people who are often still recovering from life-threatening illness. With nearly half of long-term survivors in this sample reporting at least one such burden, and with burdens linked to more intensive financial coping, the study suggests that the administrative machinery of American health insurance operates as a persistent, treatment-linked stressor in cancer care, one that persists long after the last infusion or radiation session and that no category of coverage reliably shields patients from.

Subject of Research: Administrative burdens and financial toxicity among cancer survivors by insurance type and treatment received

Article Title: Examination of insurance type and cancer treatments with administrative burdens and financial toxicity in a sample of cancer survivors

Article References: Lu, A. Z., Yi, J. C., Henrikson, N. B., Panattoni, L. E., Lowry, D., Harkey, K., & Jones, S. M. W. (2026). Examination of insurance type and cancer treatments with administrative burdens and financial toxicity in a sample of cancer survivors. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-026-02116-z

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02116-z

Keywords: cancer survivors, financial toxicity, administrative burden, prior authorization, health insurance, immunotherapy, chemotherapy, surprise bills, claim denials, radiation therapy, financial coping, Journal of Cancer Survivorship

Chest masculinization surgery, often called gender-affirming top surgery, is considered medically necessary for many transgender and nonbinary people experiencing chest dysphoria, the distress arising from a mismatch between chest anatomy and gender identity. The operation encompasses a range of techniques tailored to individual anatomy and goals, with double-incision mastectomy with free nipple grafting the most common approach. The evidence base supporting the procedure has grown considerably. Prospective studies using validated instruments have documented significant reductions in depression and anxiety alongside improvements in body image and psychosocial functioning six months after surgery. Long-term follow-up of 139 patients two or more years postoperative reported median satisfaction scores of 5 out of 5 and decisional regret scores of 0 out of 100, with no participants seeking reversal.

Population-level data reinforce these individual outcomes. An analysis of national insurance claims found significantly lower rates of antidepressant use, suicidal ideation and attempts, and substance misuse among people with gender incongruence who had undergone gender-affirming surgery. A secondary analysis of the 2015 U.S. Transgender Survey, which included 27,715 respondents, found that those who had surgery at least two years earlier had significantly lower odds of past-month psychological distress, past-year suicidal ideation, and past-year tobacco use compared with those who desired but had not yet received surgery. Critically, the analysis controlled for prior transition-related care such as counseling and hormone therapy, isolating the surgical contribution. In the 2022 U.S. Transgender Survey of 22,285 respondents, 97 percent of those who had received surgery reported greater life satisfaction afterward.

The policy backdrop to the Cincinnati study is essential to interpreting its results. Medicare reversed its exclusion of gender-affirming surgery in 2014, and in 2016 the U.S. Department of Health and Human Services implemented Section 1557 of the Affordable Care Act, expanding the definition of sex discrimination to include gender identity and thereby prohibiting insurance discrimination against gender-affirming care. Federal regulations now prohibit categorical exclusions of such care in health plans receiving federal funding, and as of 2024, twenty-four states and the District of Columbia have enacted laws or regulations barring blanket exclusions in private insurance. The volume of surgery reflects this shift: one analysis documented a 152-fold increase in gender-affirming surgeries between 2010 and 2018, with the steepest growth, 257 percent, occurring in the Midwest during the implementation period of Section 1557.

Against that backdrop, the Cincinnati team assembled its cohort using the ICD-10 diagnosis code for gender incongruence and extracted demographic, clinical, and insurance data from the electronic medical record. The 128 patients had a mean age of 26.9 years, and 79 percent identified as transgender men while 21 percent identified as nonbinary. Public insurance was the norm, covering 64 percent of patients, including 57 percent on Medicaid. The vast majority of consultations, 90 percent, occurred in 2019 or later, underscoring how rapidly demand grew in the second half of the study window. All procedures were performed by the same group of surgeons throughout, which the authors note strengthens the internal consistency of the wait-time analysis.

The insurance findings are nuanced. Overall, 27 patients, or 21 percent, received at least one denial of prior authorization, and two-thirds of those denials came from public insurers. Yet the likelihood of denial did not differ significantly between public and private coverage, at 21 percent versus 20 percent. Seventeen of the 27 denied patients were ultimately approved after resubmission, while eight did not proceed and were lost to follow-up. Nonbinary patients were significantly less likely than transgender men to experience a denial, 7 percent versus 24 percent, a difference the authors attribute in part to the fact that all nonbinary patients were engaged in psychiatric care, which may have strengthened the medical necessity documentation supporting their authorization requests.

Wait times emerged as the study’s most policy-sensitive metric. The mean interval from initial consultation to surgery was 249 days, or roughly 8.2 months, with a median of 208 days. Publicly insured patients waited an average of 259 days compared with 218 days for the privately insured, a 41-day difference that was not statistically significant. Consultation year, by contrast, was strongly associated with wait time, with the shortest waits, 186 days, recorded in 2022. Neither insurance type assessed year by year nor the duration of gender-affirming hormone therapy independently predicted how long patients waited. That last result carries practical weight: hormone therapy duration requirements embedded in insurer policies appear to do little to expedite care, suggesting that timely progression depends more on coordinated documentation from primary care and mental health clinicians and on surgeons willing to engage in the appeals process.

Surgical outcomes added a further layer of complexity. Among the 89 patients, or 70 percent of the cohort, who underwent surgery, mean tissue resected was 875.2 grams and postoperative complications occurred in 11 percent, including infections requiring antibiotics, hematomas or seromas requiring drainage, delayed wound healing, and nipple necrosis. No patient required a return to the operating room. Nonbinary patients had significantly greater mean tissue resected than transgender men, 1410.6 grams versus 742.9 grams, and more frequently opted for a no-nipple result. They also experienced a significantly higher rate of postoperative infection, 16 percent versus 1 percent, though rates of seroma, delayed healing, and revision surgery did not differ by gender identity. The authors suggest the larger resection volumes may have contributed to the infection difference and note that similar revision rates between groups imply comparable achievement of desired aesthetic outcomes.

The study’s limitations are acknowledged candidly. Spanning nearly a decade of overlapping legal and policy changes, the retrospective design cannot isolate the effect of any single reform, and the analysis was not powered for granular year-by-year comparisons. Records may have omitted contextual details, and institutional factors are difficult to disentangle from broader trends. The single-center setting in a region without state-level nondiscrimination protections limits generalizability, particularly given that an estimated 44 percent of the LGBTQ population lives in states lacking such safeguards. Nationally, disparities persist: 28 percent of 2022 U.S. Transgender Survey respondents reported avoiding medical care due to cost, and 35 percent of those assigned female at birth who sought chest surgery reported a denial in the past year, with Medicaid recipients disproportionately affected.

Even so, the core message stands out with unusual clarity for health services research. Access to chest masculinization surgery at this Midwestern center improved primarily along a temporal gradient that tracks federal policy change, not along the insurance fault line that so often divides American health care. The authors conclude that federal policy shifts were associated with meaningful improvements in access across insurance types, even in a region lacking state-level protections, while cautioning that access remains tightly linked to policy and increasingly vulnerable to reversal amid ongoing federal reconsideration of gender identity protections under Section 1557. As the legal landscape evolves, they argue, research in the regions most exposed to policy change will be critical to understanding how these dynamics shape access to medically necessary care for transgender and nonbinary adults.

Subject of Research: Trends in insurance coverage and surgical wait times for gender-affirming chest masculinization surgery among transgender and nonbinary adults in the United States

Article Title: A decade under review—trends in insurance coverage and wait times for chest masculinization surgery in the United States

Article References: A decade under review—trends in insurance coverage and wait times for chest masculinization surgery in the United States. (n.d.). https://doi.org/10.1186/s44452-026-00020-0

Image Credits: AI Generated

DOI: 10.1186/s44452-026-00020-0

Keywords: chest masculinization surgery, gender-affirming care, insurance denials, prior authorization, Affordable Care Act, Section 1557, transgender health, nonbinary patients, wait times, health policy, Medicaid, plastic surgery